Global Search

Hide Filters

Showing 1672 results

Event / Sep 01, 2025

European Society for Medical Oncology (ESMO) Congress 2025

At this year’s European Society for Medical Oncology (ESMO) Congress, we will present the latest transformative data from our oncology portfolio, sharing new data, research and science that reflect…
Event / Sep 01, 2025

European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2025

At this year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting, we will be sharing the latest data and research from our neuroscience portfolio, driven by…
Ad hoc release / Mar 23, 2022

Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR FDA also approved complementary diagnostic imaging agent, Locametz®, after radiolabeling with gallium-68 for the identification of PSMA-positive…
Press release / Jul 20, 2021

Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity

Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and…
Ad hoc release / May 18, 2018

Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention

Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-…
Press release / Jul 06, 2017

Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis

Label update includes 52 week data from CLEAR study demonstrating long-term superiority of Cosentyx® versus Stelara® in psoriasis [1],[2] Update also includes use of Cosentyx in moderate-to…
Press release / Jan 19, 2015

Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients

Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative to treatments that have significant side effects[1]; all other…
Press release / Mar 13, 2017

Novartis Kisqali® (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor

Approved based on a first-line Phase III trial that met its primary endpoint of progression-free survival (PFS) at interim analysis due to superior efficacy compared to letrozole alone[1] …
Press release / Oct 08, 2016

Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care

LEE011 (ribociclib) plus letrozole reduced the risk of progression or death by 44% over letrozole alone, significantly extending progression-free survival (PFS) across all patient subgroups…
Press release / Oct 01, 2016

Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients

Cosentyx® delivers long-lasting clear or almost clear skin (PASI 90 to PASI 100) in the vast majority of patients and continues to show a favorable safety profile over 4 years[1] New data show…

‹ Previous page
1
…
26
27
28
29
30
31
32
…
168
› Next page